Drugs / HIV-Mag pDNA
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01859325 | May 2013 → Feb 2017 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HIV-Mag pDNA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01859325 ↗ |
| Modality | Vaccine | “HIV-MAG pDNA vaccine prime” NCT01859325 ↗ |
| Route | Intramuscular | “The HIV-MAG pDNA vaccine prime and IL-12 pDNA adjuvant will be administered as 2 IM injections” NCT01859325 ↗ |